Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.
Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. Nathan PJ, et al. Among authors: davies ch. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. doi: 10.1017/S1461145712000752. Epub 2012 Aug 29. Int J Neuropsychopharmacol. 2013. PMID: 22932339 Free article. Clinical Trial.
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, Herdon HJ, Jones GA, Jeggo R, Kew JN, Mazzali A, Melarange R, Patel N, Pardoe J, Randall AD, Roberts C, Roopun A, Starr KR, Teriakidis A, Wood MD, Whittington M, Wu Z, Watson J. Langmead CJ, et al. Among authors: davies ch. Br J Pharmacol. 2008 Jul;154(5):1104-15. doi: 10.1038/bjp.2008.152. Epub 2008 May 5. Br J Pharmacol. 2008. PMID: 18454168 Free PMC article.
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. Dawson LA, et al. Among authors: davies ch. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. doi: 10.1038/sj.npp.1301549. Epub 2007 Aug 29. Neuropsychopharmacology. 2008. PMID: 17728699
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW. Dawson LA, et al. Among authors: davies ch. Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30. Eur J Pharmacol. 2010. PMID: 19879867
Gabapentin is not a GABAB receptor agonist.
Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, Charles KJ, Wood M, Davies CH, Pangalos MN. Lanneau C, et al. Among authors: davies ch. Neuropharmacology. 2001 Dec;41(8):965-75. doi: 10.1016/s0028-3908(01)00140-x. Neuropharmacology. 2001. PMID: 11747901
Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist.
Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB. Gunthorpe MJ, et al. Among authors: davies ch. Neuropharmacology. 2004 Jan;46(1):133-49. doi: 10.1016/s0028-3908(03)00305-8. Neuropharmacology. 2004. PMID: 14654105
151 results